Gapping down
In reaction to earnings/guidance:
- DNMR -11.4% (also announces planned $700 mln investment in manufacturing expansion), BFLY -7.4%, CLDX -6.9% (also provides clinical update), GOEV -5.9%, FDS -0.9%
Other news:
- WVE -24.7% (reports mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 in Huntington's disease)
- GMTX -4% (stock offering)
- LPRO -3% (stock offering)
- FREQ -1.8% (provides updates on FX-322 clinical trials; also reports 4Q20 results)
- PLMR -1.7% (approves $40 mln share repurchase program; also reaffirms adjusted net income guidance for 2021)
- AZN -1.2% (Some Canadian provinces suspend vaccine for people under 55, according to Forbes)
- ATVI -0.9% (promotes Armin Zerza to CFO; on track to exceed prior outlook for Q1)
Analyst comments:
- APA -2.2% (downgraded to Hold from Buy at Truist)
- ASND -1.6% (downgraded to Perform from Outperform at Oppenheimer)
- BSMX -0.9% (downgraded to Hold from Buy at HSBC Securities)